<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063540</url>
  </required_header>
  <id_info>
    <org_study_id>16-API-01</org_study_id>
    <nct_id>NCT04063540</nct_id>
  </id_info>
  <brief_title>Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura</brief_title>
  <acronym>APAM</acronym>
  <official_title>Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology
      of migraine making these channels a therapeutic target of migraine disease. The implication
      of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the
      most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a
      mouse model, cortical spreading depression is inhibited by different Acid-Sensing Ion Channel
      blockers including amiloride which is a non-selective blocker of the Acid-Sensing Ion
      Channel-1 channel. From a translational perspective, an efficacy of amiloride on a series of
      migraine patients suffering from severe aura in open conditions. The APAM study is a
      proof-of-concept study that aims to evaluate the effect of amiloride in the prophylaxis of
      migraine with aura. This is a randomized crossover study versus placebo conducted in 3 French
      headache centers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of attacks with aura, with or without headache.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days with migraine headache, with or without aura</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional repercussion</measure>
    <time_frame>12 weeks</time_frame>
    <description>Anxiety and depression score on the Hospital Anxiety and Depression scale scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Migraine With Aura</condition>
  <arm_group>
    <arm_group_label>placebo-amiloride</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amiloride -placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Treatment by Amiloride vs placebo in crossover</description>
    <arm_group_label>amiloride -placebo</arm_group_label>
    <arm_group_label>placebo-amiloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Treatment by Amiloride vs placebo in crossover</description>
    <arm_group_label>amiloride -placebo</arm_group_label>
    <arm_group_label>placebo-amiloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of migraine with aura code

          -  At least 1 aura with aura per month in the 3 months prior to inclusion

          -  No prophylactic antimigraine treatment for at least 1 month prior to inclusion

          -  For women of childbearing age, use of a reliable contraceptive method at least 3
             months before and 1 month after the study

          -  Signature of written informed consent

          -  Patient affiliated with Social Security

        Exclusion Criteria:

          -  Existence of contraindication to taking amiloride:

               -  Known hypersensitivity to the molecule

               -  Hyperkalemia (potassium level (&gt; 5.5 mmol / l))

               -  Use of another hyperkalemic diuretic or potassium salts

               -  Renal insufficiency (clearance &lt;60 ml / min)

               -  Severe hepatocellular insufficiency

               -  In combination with lithium, converting enzyme inhibitors, angiotensin II
                  inhibitors (except if there is hypokalemia), ciclosporin, tacrolimus,
                  non-antiarrhythmic drugs giving torsades de pointes

          -  Cardiovascular and renal history, for subjects over 75 years old

          -  Patient, who from an investigator's point of view would not be compliant to the
             procedure of the study

          -  Pregnant or lactating patient

          -  Patient under trusteeship, under guardianship, protected by law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie PIQUET, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie PIQUET, Dr</last_name>
    <phone>04 92 03 84 74</phone>
    <email>piquet.e@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel LANTERI-MINET, Dr</last_name>
    <phone>04 92 03 79 46</phone>
    <email>lanteri-minet.m@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marly</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne DONNET, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne DUCROS, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev Neurol. 2013 Nov;9(11):637-44. doi: 10.1038/nrneurol.2013.192. Epub 2013 Sep 17. Review.</citation>
    <PMID>24042483</PMID>
  </reference>
  <results_reference>
    <citation>Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006 Apr;59(4):652-61.</citation>
    <PMID>16450381</PMID>
  </results_reference>
  <results_reference>
    <citation>Ligthart L, Boomsma DI, Martin NG, Stubbe JH, Nyholt DR. Migraine with aura and migraine without aura are not distinct entities: further evidence from a large Dutch population study. Twin Res Hum Genet. 2006 Feb;9(1):54-63.</citation>
    <PMID>16611468</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>aura</keyword>
  <keyword>Amiloride</keyword>
  <keyword>acid-sensing ion channel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

